Need help finding what you are looking for?
Contact Us
PUBLISHER: 360iResearch | PRODUCT CODE: 2170785
PUBLISHER: 360iResearch | PRODUCT CODE: 2170785
Lung Cancer Market - Global Forecast 2026-2032
PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The Lung Cancer Market is projected to grow by USD 60.65 billion at a CAGR of 8.77% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 33.66 billion |
| Estimated Year [2026] | USD 36.52 billion |
| Forecast Year [2032] | USD 60.65 billion |
| CAGR (%) | 8.77% |
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. New Revenue Opportunities
- 3.5. Next-Generation Business Models
- 3.6. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Lung Cancer Market, by Cancer Type
- 7.1. Introduction
- 7.2. Non-Small Cell Lung Cancer
- 7.2.1. Adenocarcinoma
- 7.2.2. Large Cell Carcinoma
- 7.2.3. Squamous Cell Carcinoma
- 7.3. Small Cell Lung Cancer
- 7.4. Introduction
- 7.5. Non-Small Cell Lung Cancer
- 7.5.1. Adenocarcinoma
- 7.5.2. Large Cell Carcinoma
- 7.5.3. Squamous Cell Carcinoma
- 7.6. Small Cell Lung Cancer
8. Lung Cancer Market, by Stage
- 8.1. Introduction
- 8.2. Stage I
- 8.3. Stage II
- 8.4. Stage III
- 8.5. Stage IV
- 8.6. Introduction
- 8.7. Stage I
- 8.8. Stage II
- 8.9. Stage III
- 8.10. Stage IV
9. Lung Cancer Market, by Cancer Type
- 9.1. Introduction
- 9.2. Non-Small Cell Lung Cancer
- 9.2.1. Adenocarcinoma
- 9.2.2. Large Cell Carcinoma
- 9.2.3. Squamous Cell Carcinoma
- 9.3. Small Cell Lung Cancer
- 9.4. Introduction
- 9.5. Non-Small Cell Lung Cancer
- 9.5.1. Adenocarcinoma
- 9.5.2. Large Cell Carcinoma
- 9.5.3. Squamous Cell Carcinoma
- 9.6. Small Cell Lung Cancer
10. Lung Cancer Market, by Stage
- 10.1. Introduction
- 10.2. Stage I
- 10.3. Stage II
- 10.4. Stage III
- 10.5. Stage IV
- 10.6. Introduction
- 10.7. Stage I
- 10.8. Stage II
- 10.9. Stage III
- 10.10. Stage IV
11. Lung Cancer Market, by Therapy Type
- 11.1. Introduction
- 11.2. Radiotherapy
- 11.2.1. Brachytherapy
- 11.2.2. External Beam (3D-CRT/IMRT/VMAT)
- 11.2.3. Proton Therapy
- 11.2.4. Stereotactic Body Radiotherapy (SBRT/SABR)
- 11.3. Supportive Care
- 11.3.1. Hematologic Support
- 11.3.2. Nutrition & Rehabilitation
- 11.3.3. Symptom Management
- 11.4. Surgery
- 11.4.1. Lobectomy
- 11.4.2. Pneumonectomy
- 11.4.3. Segmentectomy/Wedge Resection
- 11.5. Systemic Therapy
- 11.5.1. Anti-Angiogenic Therapy
- 11.5.2. Antibody-Drug Conjugates
- 11.5.3. Chemotherapy
- 11.5.4. Immunotherapy
- 11.5.4.1. CTLA-4 Inhibitors
- 11.5.4.2. PD-1 Inhibitors
- 11.5.4.3. PD-L1 Inhibitors
- 11.5.5. Targeted Therapy
- 11.5.5.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
- 11.5.5.2. BRAF Inhibitors
- 11.5.5.3. EGFR Inhibitors
12. Lung Cancer Market, by Line Of Therapy
- 12.1. Introduction
- 12.2. First-Line
- 12.3. Second-Line
- 12.4. Third-Line & Beyond
13. Lung Cancer Market, by Route Of Administration
- 13.1. Introduction
- 13.2. Inhaled
- 13.3. Intravenous
- 13.4. Oral
- 13.5. Subcutaneous
14. Lung Cancer Market, by Age Group
- 14.1. Introduction
- 14.2. 45-64
- 14.3. 65-74
- 14.4. 75 & Over
- 14.5. Under 45
15. Lung Cancer Market, by Distribution Channel
- 15.1. Introduction
- 15.2. Hospital Pharmacies
- 15.3. Online Pharmacies
- 15.4. Retail Pharmacies
16. Lung Cancer Market, by End User
- 16.1. Introduction
- 16.2. Ambulatory Surgical Centers
- 16.3. Diagnostic Laboratories
- 16.4. Hospitals
- 16.5. Oncology Specialty Clinics
- 16.6. Radiotherapy Centers
17. Lung Cancer Market, by Setting Of Care
- 17.1. Introduction
- 17.2. Home Care
- 17.3. Inpatient
- 17.4. Outpatient
18. Lung Cancer Market, by Region
- 18.1. Introduction
- 18.2. Asia-Pacific
- 18.3. Europe
- 18.4. North America
- 18.5. Latin America
- 18.6. Africa
- 18.7. Middle East
19. Lung Cancer Market, by Group
- 19.1. Introduction
- 19.2. NATO
- 19.3. G7
- 19.4. European Union
- 19.5. BRICS
- 19.6. ASEAN
- 19.7. GCC
20. Lung Cancer Market, by Country
- 20.1. Introduction
- 20.2. United States
- 20.3. China
- 20.4. Germany
- 20.5. Canada
- 20.6. Japan
- 20.7. India
- 20.8. Brazil
- 20.9. United Kingdom
- 20.10. Mexico
- 20.11. France
- 20.12. Italy
- 20.13. Australia
- 20.14. Russia
- 20.15. South Korea
- 20.16. Spain
21. Competitive Landscape
- 21.1. Market Share Analysis, 2025
- 21.2. FPNV Positioning Matrix, 2025
- 21.3. Market Concentration Analysis, 2025
- 21.3.1. Concentration Ratio (CR)
- 21.3.2. Herfindahl Hirschman Index (HHI)
- 21.4. Recent Developments & Impact Analysis, 2025
- 21.5. Product Portfolio Analysis, 2025
- 21.6. Benchmarking Analysis, 2025
22. Company Profiles
- 22.1. AbbVie Inc.
- 22.2. Amgen Inc.
- 22.3. Astellas Pharma Inc.
- 22.4. AstraZeneca PLC
- 22.5. Bayer AG
- 22.6. Boehringer Ingelheim International GmbH
- 22.7. Bristol-Myers Squibb Company
- 22.8. Candel Therapeutics, Inc.
- 22.9. Cullinan Therapeutics, Inc.
- 22.10. Daiichi Sankyo, Inc.
- 22.11. Dr. Reddy's Laboratories Ltd.
- 22.12. Eli Lilly and Company
- 22.13. F. Hoffmann-La Roche Ltd
- 22.14. Fresenius Kabi AG
- 22.15. GlaxoSmithKline plc
- 22.16. Innovent Biologics, Inc.
- 22.17. Jazz Pharmaceuticals plc
- 22.18. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- 22.19. Johnson & Johnson Services, Inc.
- 22.20. MAIA Biotechnology, Inc.
- 22.21. Merck & Co., Inc.
- 22.22. Novartis AG
- 22.23. Nuvalent
- 22.24. OS Therapies Inc.
- 22.25. OSE Immunotherapeutics
- 22.26. Pfizer Inc.
- 22.27. Regeneron Pharmaceuticals Inc.
- 22.28. Sanofi S.A
- 22.29. Shanghai Henlius Biotech, Inc.
- 22.30. Summit Therapeutics Inc.
- 22.31. Takeda Pharmaceutical Company Limited
- 22.32. Teva Pharmaceutical Industries Ltd.
- 22.33. Viatris Inc.
Product Code: MRR-ED4AB916AB9B
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. New Revenue Opportunities
- 3.5. Next-Generation Business Models
- 3.6. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Lung Cancer Market, by Cancer Type
- 7.1. Introduction
- 7.2. Non-Small Cell Lung Cancer
- 7.2.1. Adenocarcinoma
- 7.2.2. Large Cell Carcinoma
- 7.2.3. Squamous Cell Carcinoma
- 7.3. Small Cell Lung Cancer
- 7.4. Introduction
- 7.5. Non-Small Cell Lung Cancer
- 7.5.1. Adenocarcinoma
- 7.5.2. Large Cell Carcinoma
- 7.5.3. Squamous Cell Carcinoma
- 7.6. Small Cell Lung Cancer
8. Lung Cancer Market, by Stage
- 8.1. Introduction
- 8.2. Stage I
- 8.3. Stage II
- 8.4. Stage III
- 8.5. Stage IV
- 8.6. Introduction
- 8.7. Stage I
- 8.8. Stage II
- 8.9. Stage III
- 8.10. Stage IV
9. Lung Cancer Market, by Cancer Type
- 9.1. Introduction
- 9.2. Non-Small Cell Lung Cancer
- 9.2.1. Adenocarcinoma
- 9.2.2. Large Cell Carcinoma
- 9.2.3. Squamous Cell Carcinoma
- 9.3. Small Cell Lung Cancer
- 9.4. Introduction
- 9.5. Non-Small Cell Lung Cancer
- 9.5.1. Adenocarcinoma
- 9.5.2. Large Cell Carcinoma
- 9.5.3. Squamous Cell Carcinoma
- 9.6. Small Cell Lung Cancer
10. Lung Cancer Market, by Stage
- 10.1. Introduction
- 10.2. Stage I
- 10.3. Stage II
- 10.4. Stage III
- 10.5. Stage IV
- 10.6. Introduction
- 10.7. Stage I
- 10.8. Stage II
- 10.9. Stage III
- 10.10. Stage IV
11. Lung Cancer Market, by Therapy Type
- 11.1. Introduction
- 11.2. Radiotherapy
- 11.2.1. Brachytherapy
- 11.2.2. External Beam (3D-CRT/IMRT/VMAT)
- 11.2.3. Proton Therapy
- 11.2.4. Stereotactic Body Radiotherapy (SBRT/SABR)
- 11.3. Supportive Care
- 11.3.1. Hematologic Support
- 11.3.2. Nutrition & Rehabilitation
- 11.3.3. Symptom Management
- 11.4. Surgery
- 11.4.1. Lobectomy
- 11.4.2. Pneumonectomy
- 11.4.3. Segmentectomy/Wedge Resection
- 11.5. Systemic Therapy
- 11.5.1. Anti-Angiogenic Therapy
- 11.5.2. Antibody-Drug Conjugates
- 11.5.3. Chemotherapy
- 11.5.4. Immunotherapy
- 11.5.4.1. CTLA-4 Inhibitors
- 11.5.4.2. PD-1 Inhibitors
- 11.5.4.3. PD-L1 Inhibitors
- 11.5.5. Targeted Therapy
- 11.5.5.1. Anaplastic Lymphoma Kinase (ALK) Inhibitors
- 11.5.5.2. BRAF Inhibitors
- 11.5.5.3. EGFR Inhibitors
12. Lung Cancer Market, by Line Of Therapy
- 12.1. Introduction
- 12.2. First-Line
- 12.3. Second-Line
- 12.4. Third-Line & Beyond
13. Lung Cancer Market, by Route Of Administration
- 13.1. Introduction
- 13.2. Inhaled
- 13.3. Intravenous
- 13.4. Oral
- 13.5. Subcutaneous
14. Lung Cancer Market, by Age Group
- 14.1. Introduction
- 14.2. 45-64
- 14.3. 65-74
- 14.4. 75 & Over
- 14.5. Under 45
15. Lung Cancer Market, by Distribution Channel
- 15.1. Introduction
- 15.2. Hospital Pharmacies
- 15.3. Online Pharmacies
- 15.4. Retail Pharmacies
16. Lung Cancer Market, by End User
- 16.1. Introduction
- 16.2. Ambulatory Surgical Centers
- 16.3. Diagnostic Laboratories
- 16.4. Hospitals
- 16.5. Oncology Specialty Clinics
- 16.6. Radiotherapy Centers
17. Lung Cancer Market, by Setting Of Care
- 17.1. Introduction
- 17.2. Home Care
- 17.3. Inpatient
- 17.4. Outpatient
18. Lung Cancer Market, by Region
- 18.1. Introduction
- 18.2. Asia-Pacific
- 18.3. Europe
- 18.4. North America
- 18.5. Latin America
- 18.6. Africa
- 18.7. Middle East
19. Lung Cancer Market, by Group
- 19.1. Introduction
- 19.2. NATO
- 19.3. G7
- 19.4. European Union
- 19.5. BRICS
- 19.6. ASEAN
- 19.7. GCC
20. Lung Cancer Market, by Country
- 20.1. Introduction
- 20.2. United States
- 20.3. China
- 20.4. Germany
- 20.5. Canada
- 20.6. Japan
- 20.7. India
- 20.8. Brazil
- 20.9. United Kingdom
- 20.10. Mexico
- 20.11. France
- 20.12. Italy
- 20.13. Australia
- 20.14. Russia
- 20.15. South Korea
- 20.16. Spain
21. Competitive Landscape
- 21.1. Market Share Analysis, 2025
- 21.2. FPNV Positioning Matrix, 2025
- 21.3. Market Concentration Analysis, 2025
- 21.3.1. Concentration Ratio (CR)
- 21.3.2. Herfindahl Hirschman Index (HHI)
- 21.4. Recent Developments & Impact Analysis, 2025
- 21.5. Product Portfolio Analysis, 2025
- 21.6. Benchmarking Analysis, 2025
22. Company Profiles
- 22.1. AbbVie Inc.
- 22.2. Amgen Inc.
- 22.3. Astellas Pharma Inc.
- 22.4. AstraZeneca PLC
- 22.5. Bayer AG
- 22.6. Boehringer Ingelheim International GmbH
- 22.7. Bristol-Myers Squibb Company
- 22.8. Candel Therapeutics, Inc.
- 22.9. Cullinan Therapeutics, Inc.
- 22.10. Daiichi Sankyo, Inc.
- 22.11. Dr. Reddy's Laboratories Ltd.
- 22.12. Eli Lilly and Company
- 22.13. F. Hoffmann-La Roche Ltd
- 22.14. Fresenius Kabi AG
- 22.15. GlaxoSmithKline plc
- 22.16. Innovent Biologics, Inc.
- 22.17. Jazz Pharmaceuticals plc
- 22.18. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- 22.19. Johnson & Johnson Services, Inc.
- 22.20. MAIA Biotechnology, Inc.
- 22.21. Merck & Co., Inc.
- 22.22. Novartis AG
- 22.23. Nuvalent
- 22.24. OS Therapies Inc.
- 22.25. OSE Immunotherapeutics
- 22.26. Pfizer Inc.
- 22.27. Regeneron Pharmaceuticals Inc.
- 22.28. Sanofi S.A
- 22.29. Shanghai Henlius Biotech, Inc.
- 22.30. Summit Therapeutics Inc.
- 22.31. Takeda Pharmaceutical Company Limited
- 22.32. Teva Pharmaceutical Industries Ltd.
- 22.33. Viatris Inc.
Product Code: MRR-ED4AB916AB9B
LIST OF FIGURES
- FIGURE 1. GLOBAL LUNG CANCER MARKET, YEARS CONSIDERED FOR THE STUDY
- FIGURE 2. GLOBAL LUNG CANCER MARKET, RESEARCH DESIGN
- FIGURE 3. GLOBAL LUNG CANCER MARKET, RESEARCH FRAMEWORK
- FIGURE 4. GLOBAL LUNG CANCER MARKET, DATA TRIANGULATION
- FIGURE 5. GLOBAL LUNG CANCER MARKET SIZE, 2024-2032 (USD MILLION)
- FIGURE 6. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
- FIGURE 7. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 8. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
- FIGURE 9. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 10. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
- FIGURE 11. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 12. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
- FIGURE 13. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 14. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
- FIGURE 15. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 16. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
- FIGURE 17. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 18. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
- FIGURE 19. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 20. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
- FIGURE 21. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 22. GLOBAL LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
- FIGURE 23. GLOBAL LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 24. GLOBAL LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
- FIGURE 25. GLOBAL LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 26. GLOBAL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
- FIGURE 27. GLOBAL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 28. GLOBAL LUNG CANCER MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
- FIGURE 29. GLOBAL LUNG CANCER MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 30. GLOBAL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
- FIGURE 31. GLOBAL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 32. GLOBAL LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2032 (%)
- FIGURE 33. GLOBAL LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 34. GLOBAL LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2025 VS 2032 (%)
- FIGURE 35. GLOBAL LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 36. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2032 (%)
- FIGURE 37. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 38. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
- FIGURE 39. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 40. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
- FIGURE 41. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
- FIGURE 42. GLOBAL LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
- FIGURE 43. GLOBAL LUNG CANCER MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
LIST OF TABLES
- TABLE 1. GLOBAL LUNG CANCER MARKET SEGMENTATION & COVERAGE
- TABLE 2. GLOBAL LUNG CANCER MARKET SIZE, 2017-2032 (USD MILLION)
- TABLE 3. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 7. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 8. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 9. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 10. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 11. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 12. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 13. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 14. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 15. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 16. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 17. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 18. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 19. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 23. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 24. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 25. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 26. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 27. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 28. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 29. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 30. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 31. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 32. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 33. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 34. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 35. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 36. GLOBAL STAGE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 37. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 38. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 39. GLOBAL STAGE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 40. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 41. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 42. GLOBAL STAGE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 43. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 44. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 45. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 46. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 47. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 48. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 49. GLOBAL STAGE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 50. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 51. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 52. GLOBAL STAGE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 53. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 54. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 55. GLOBAL STAGE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 56. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 57. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 58. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 59. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 60. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 61. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 62. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 63. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 64. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 65. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 66. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 67. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 68. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 69. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 70. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 71. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 72. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 73. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 74. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 75. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 76. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 77. GLOBAL LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 78. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 79. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 80. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 81. GLOBAL ADENOCARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 82. GLOBAL ADENOCARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 83. GLOBAL ADENOCARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 84. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 85. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 86. GLOBAL LARGE CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 87. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 88. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 89. GLOBAL SQUAMOUS CELL CARCINOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 90. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 91. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 92. GLOBAL SMALL CELL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 93. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 94. GLOBAL STAGE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 95. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 96. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 97. GLOBAL STAGE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 98. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 99. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 100. GLOBAL STAGE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 101. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 102. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 103. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 104. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 105. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 106. GLOBAL LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 107. GLOBAL STAGE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 108. GLOBAL STAGE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 109. GLOBAL STAGE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 110. GLOBAL STAGE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 111. GLOBAL STAGE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 112. GLOBAL STAGE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 113. GLOBAL STAGE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 114. GLOBAL STAGE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 115. GLOBAL STAGE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 116. GLOBAL STAGE IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 117. GLOBAL STAGE IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 118. GLOBAL STAGE IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 119. GLOBAL LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 120. GLOBAL RADIOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 121. GLOBAL RADIOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 122. GLOBAL RADIOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 123. GLOBAL BRACHYTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 124. GLOBAL BRACHYTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 125. GLOBAL BRACHYTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 126. GLOBAL EXTERNAL BEAM (3D-CRT/IMRT/VMAT) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 127. GLOBAL EXTERNAL BEAM (3D-CRT/IMRT/VMAT) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 128. GLOBAL EXTERNAL BEAM (3D-CRT/IMRT/VMAT) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 129. GLOBAL PROTON THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 130. GLOBAL PROTON THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 131. GLOBAL PROTON THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 132. GLOBAL STEREOTACTIC BODY RADIOTHERAPY (SBRT/SABR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 133. GLOBAL STEREOTACTIC BODY RADIOTHERAPY (SBRT/SABR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 134. GLOBAL STEREOTACTIC BODY RADIOTHERAPY (SBRT/SABR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 135. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 136. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 137. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 138. GLOBAL HEMATOLOGIC SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 139. GLOBAL HEMATOLOGIC SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 140. GLOBAL HEMATOLOGIC SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 141. GLOBAL NUTRITION & REHABILITATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 142. GLOBAL NUTRITION & REHABILITATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 143. GLOBAL NUTRITION & REHABILITATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 144. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 145. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 146. GLOBAL SYMPTOM MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 147. GLOBAL SURGERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 148. GLOBAL SURGERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 149. GLOBAL SURGERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 150. GLOBAL LOBECTOMY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 151. GLOBAL LOBECTOMY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 152. GLOBAL LOBECTOMY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 153. GLOBAL PNEUMONECTOMY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 154. GLOBAL PNEUMONECTOMY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 155. GLOBAL PNEUMONECTOMY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 156. GLOBAL SEGMENTECTOMY/WEDGE RESECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 157. GLOBAL SEGMENTECTOMY/WEDGE RESECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 158. GLOBAL SEGMENTECTOMY/WEDGE RESECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 159. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 160. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 161. GLOBAL SYSTEMIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 162. GLOBAL ANTI-ANGIOGENIC THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 163. GLOBAL ANTI-ANGIOGENIC THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 164. GLOBAL ANTI-ANGIOGENIC THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 165. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 166. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 167. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 168. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 169. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 170. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 171. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 172. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 173. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 174. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 175. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 176. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 177. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 178. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 179. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 180. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 181. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 182. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 183. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 184. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 185. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 186. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 187. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 188. GLOBAL ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 189. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 190. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 191. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 192. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 193. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 194. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 195. GLOBAL LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 196. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 197. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 198. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 199. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 200. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 201. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 202. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 203. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 204. GLOBAL THIRD-LINE & BEYOND MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 205. GLOBAL LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 206. GLOBAL INHALED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 207. GLOBAL INHALED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 208. GLOBAL INHALED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 209. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 210. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 211. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 212. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 213. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 214. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 215. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 216. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 217. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 218. GLOBAL LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 219. GLOBAL 45-64 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 220. GLOBAL 45-64 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 221. GLOBAL 45-64 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 222. GLOBAL 65-74 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 223. GLOBAL 65-74 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 224. GLOBAL 65-74 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 225. GLOBAL 75 & OVER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 226. GLOBAL 75 & OVER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 227. GLOBAL 75 & OVER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 228. GLOBAL UNDER 45 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 229. GLOBAL UNDER 45 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 230. GLOBAL UNDER 45 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 231. GLOBAL LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 232. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 233. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 234. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 235. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 236. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 237. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 238. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 239. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 240. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 241. GLOBAL LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 242. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 243. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 244. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 245. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 246. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 247. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 248. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 249. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 250. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 251. GLOBAL ONCOLOGY SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 252. GLOBAL ONCOLOGY SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 253. GLOBAL ONCOLOGY SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 254. GLOBAL RADIOTHERAPY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 255. GLOBAL RADIOTHERAPY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 256. GLOBAL RADIOTHERAPY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 257. GLOBAL LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 258. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 259. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 260. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 261. GLOBAL INPATIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 262. GLOBAL INPATIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 263. GLOBAL INPATIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 264. GLOBAL OUTPATIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 265. GLOBAL OUTPATIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
- TABLE 266. GLOBAL OUTPATIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
- TABLE 267. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 268. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 269. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 270. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 271. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 272. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 273. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 274. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 275. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 276. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 277. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 278. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 279. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 280. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 281. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 282. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 283. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 284. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 285. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 286. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 287. ASIA-PACIFIC LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 288. EUROPE LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 289. EUROPE LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 290. EUROPE LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 291. EUROPE LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 292. EUROPE LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 293. EUROPE LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 294. EUROPE LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 295. EUROPE LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 296. EUROPE LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 297. EUROPE LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 298. EUROPE LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 299. EUROPE LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 300. EUROPE LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 301. EUROPE LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 302. EUROPE LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 303. EUROPE LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 304. EUROPE LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 305. EUROPE LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 306. EUROPE LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 307. EUROPE LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 308. NORTH AMERICA LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 309. NORTH AMERICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 310. NORTH AMERICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 311. NORTH AMERICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 312. NORTH AMERICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 313. NORTH AMERICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 314. NORTH AMERICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 315. NORTH AMERICA LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 316. NORTH AMERICA LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 317. NORTH AMERICA LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 318. NORTH AMERICA LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 319. NORTH AMERICA LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 320. NORTH AMERICA LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 321. NORTH AMERICA LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 322. NORTH AMERICA LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 323. NORTH AMERICA LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 324. NORTH AMERICA LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 325. NORTH AMERICA LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 326. NORTH AMERICA LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 327. NORTH AMERICA LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 328. LATIN AMERICA LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 329. LATIN AMERICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 330. LATIN AMERICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 331. LATIN AMERICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 332. LATIN AMERICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 333. LATIN AMERICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 334. LATIN AMERICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 335. LATIN AMERICA LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 336. LATIN AMERICA LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 337. LATIN AMERICA LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 338. LATIN AMERICA LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 339. LATIN AMERICA LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 340. LATIN AMERICA LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 341. LATIN AMERICA LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 342. LATIN AMERICA LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 343. LATIN AMERICA LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 344. LATIN AMERICA LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 345. LATIN AMERICA LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 346. LATIN AMERICA LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 347. LATIN AMERICA LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 348. AFRICA LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 349. AFRICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 350. AFRICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 351. AFRICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 352. AFRICA LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 353. AFRICA LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 354. AFRICA LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 355. AFRICA LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 356. AFRICA LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 357. AFRICA LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 358. AFRICA LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 359. AFRICA LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 360. AFRICA LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 361. AFRICA LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 362. AFRICA LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 363. AFRICA LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 364. AFRICA LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 365. AFRICA LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 366. AFRICA LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 367. AFRICA LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 368. MIDDLE EAST LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
- TABLE 369. MIDDLE EAST LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 370. MIDDLE EAST LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 371. MIDDLE EAST LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 372. MIDDLE EAST LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2017-2032 (USD MILLION)
- TABLE 373. MIDDLE EAST LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2017-2032 (USD MILLION)
- TABLE 374. MIDDLE EAST LUNG CANCER MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
- TABLE 375. MIDDLE EAST LUNG CANCER MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
- TABLE 376. MIDDLE EAST LUNG CANCER MARKET SIZE, BY RADIOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 377. MIDDLE EAST LUNG CANCER MARKET SIZE, BY SUPPORTIVE CARE, 2017-2032 (USD MILLION)
- TABLE 378. MIDDLE EAST LUNG CANCER MARKET SIZE, BY SURGERY, 2017-2032 (USD MILLION)
- TABLE 379. MIDDLE EAST LUNG CANCER MARKET SIZE, BY SYSTEMIC THERAPY, 2017-2032 (USD MILLION)
- TABLE 380. MIDDLE EAST LUNG CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2017-2032 (USD MILLION)
- TABLE 381. MIDDLE EAST LUNG CANCER MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
- TABLE 382. MIDDLE EAST LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
- TABLE 383. MIDDLE EAST LUNG CANCER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
- TABLE 384. MIDDLE EAST LUNG CANCER MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
- TABLE 385. MIDDLE EAST LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
- TABLE 386. MIDDLE EAST LUNG CANCER MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
- TABLE 387. MIDDLE EAST LUNG CANCER MARKET SIZE, BY SETTING OF CARE, 2017-2032 (USD MILLION)
- TABLE 388. GLOBAL LUNG CANCER MARKET SIZE, BY
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.